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1. Introduction 
Regulation of nutrient balance by the liver is important to ensure whole body metabolic 
control. Hepatic expression of genes involved in lipid and glucose metabolism is tightly 
regulated in response to nutritional cues, such as glucose and insulin. In response to dietary 
carbohydrates, the liver converts excess glucose into fat for storage through de novo 
lipogenesis. The liver X receptors (LXRα and LXRβ) are important transcriptional regulators 
of this process. LXRs are classically known as oxysterol sensing nuclear receptors that 
heterodimerize with the retinoic X receptor (RXR) family and activate transcription of 
nutrient sensing transcription factors such as sterol regulatory element-binding protein 1c 
(SREBP1c) (Repa et al., 2000; Yoshikawa et al., 2002; Liang et al., 2002) and carbohydrate 
response element-binding protein (ChREBP) (Cha & Repa, 2007). LXR also induces the 
transcription of the lipogenic enzyme genes fatty acid synthase (FAS), stearoyl-Coenzyme A 
desaturase (SCD1) and Acetyl CoA carboxylase (ACC), alone or in concert with SREBP1c 
and/or ChREBP (Chu et al., 2006; Joseph et al., 2002; Talukdar & Hillgartner, 2006). LXR 
activate transcription of hepatic lipogenic genes in response to feeding, which is believed to 
be mediated by insulin (Tobin et al., 2002). The mechanisms by which insulin activates LXR-
mediated gene expression is not clearly understood, but may involve production of 
endogenous ligand for LXRs and/or act by signal transduction mechanisms downstream of 
the insulin receptor (IR). Both glucose and insulin regulate de novo lipogenesis, however, 
some lipogenic genes can be regulated by glucose without the need of insulin which has 
been shown for SREBP1c (Hasty et al., 2000; Matsuzaka et al., 2004). A well known glucose-
mediator in liver is ChREBP, an important regulator of de novo lipogenesis in response to 
glucose (Yamashita et al., 2001). ChREBP is activated by glucose via hexose- and pentose-
phosphate-dependent mechanisms involving dephosphorylation of ChREBP and 
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translocation to the nucleus (Havula & Hietakangas, 2012). Interestingly, both LXR and 
ChREBP were recently shown to be post-translationally modified by O-linked -N-
acetylglucosamine (O-GlcNAc) in response to glucose potentiating their lipogenic 
capacity (Anthonisen et al., 2010; Guinez et al., 2011). Glucose flux through the 
hexosamine signaling pathway generates UDP-N-acetyl-glucosamine (UDP-GlcNAc), a 
substrate for O-GlcNAc modification of nucleocytoplasmic proteins by the enzyme O-
GlcNAc transferase (OGT). We have shown that O-GlcNAcylation of LXR is increased in 
mouse livers in response to feeding and in livers from hyperglycemic diabetic mice 
potentiating SREBP1c expression (Anthonisen et al., 2010). Furthermore, preliminary 
studies in our laboratory indicate that LXR potentiate ChREBP activity under 
hyperglycemic conditions establishing a link between glucose metabolism, LXR and 
ChREBP. These observations suggest that LXR, SREBP1c and ChREBP contribute to 
converting carbohydrates into fat in a cooperative manner in response to high circulating 
glucose levels and that O-GlcNAc signaling plays a role in this process. As O-GlcNAc 
cycling appear to be essential for proper insulin signaling and the sensitivity of OGT to 
glucose increases with decreasing insulin signaling (Mondoux et al., 2011; Hanover et al., 
2010) the relative roles of LXR, SREBP1c and ChREBP in regulating de novo lipogenesis in 
response to feeding and modification by O-GlcNAc signaling under insulin sensitive and 
insulin resistant conditions will be discussed.  
2. Liver X Receptors (LXR) 
2.1. LXR structure and function 
LXR(NR1H3) and LXR (NR1H2) are ligand-activated transcription factors belonging to 
the nuclear receptor (NR) superfamily (Lehmann JM (Lehmann et al., 1997; Willy et al., 1995; 
Janowski et al., 1996). LXR is primarily expressed in metabolically active tissues, such as 
liver, intestine, adipose tissue, kidney and macrophages, whereas LXR is ubiquitously 
expressed (Apfel et al., 1994; Teboul et al., 1995; Teboul et al., 1995). LXRs are intracellular 
sensors of cholesterol and oxidized cholesterol derivatives (oxysterols) have been identified 
as their endogenous ligands (Janowski et al., 1996; Lehmann et al., 1997). The two isotypes 
originates from two different genes on separate chromosomes, but share the same modular 
structure, which is characteristic of most NRs (Fig. 1). 
 
Figure 1. Structure of the LXRs 
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The DNA-binding domain (DBD) and the ligand binding domain (LBD) are highly 
structured domains. LXRα and LXRβ share 78 % amino acid sequence identity in these 
regions, while the N-terminal domain (NTD) and the hinge domain are far more disordered 
and less conserved. DNA binding requires dimerization with RXR. Transactivation by the 
LXRs is mediated through the ligand independent activation function (AF1) in NTD and the 
ligand dependent activation function 2 (AF2) in the LBD. Binding of a ligand to the 
hydrophobic ligand binding pocket leads to a conformational change that releases 
corepressors (CR) and exposes binding sites for coactivators (CA), recruiting the general 
transcription machinery and RNA polymerase II (RNA Pol II) (Fig. 2). This leads to changes 
in LXR dependent gene expression. The interactions with coregulators can also occur 
independently of ligand to AF1, however this is far less characterized. Upon activation, 
LXRs regulate a number of genes involved in lipid, cholesterol and glucose metabolism by 
binding to LXR response elements (LXREs) in their promoter region. These consist of a 
direct repeat of the nucleotide hexamer AGGTCA spaced by four nucleotides. Insights into 
LXR function in metabolism was provided by the generation of LXR mutant mice. These 
mice accumulate hepatic cholesterol, ultimately causing liver dysfunction (Peet et al., 1998; 
Ulven et al., 2005). It was found that LXRcontrols cholesterol metabolism by conversion of 
cholesterol to bile acid by induction of the cholesterol 7 alpha-hydroxylase (Cyp7A1) gene, 
biliary cholesterol excretion and cholesterol efflux via induction of ABCG5/8 and 
ABCA1/ABCG1, respectively (Lehmann et al., 1997; Chiang et al., 2001; Yu et al., 2003; Repa 
et al., 2002; Graf et al., 2002; Costet et al., 2000; Sabol et al., 2005; Venkateswaran et al., 2000; 
Venkateswaran et al., 2000). LXRs are strongly implicated in the development of metabolic 
disorders and associated pathologies, notably, hyperlipidemia and atherosclerosis (Peet et 
al., 1998; Calkin & Tontonoz, 2010). Thus, LXRs are key players in maintaining metabolic 
homeostasis in health and disease by regulating inflammation and lipid/carbohydrate 
metabolism. 
 
Figure 2. Activation of LXR by coregulator switching 
2.2. Modulation of LXR activity by coregulators and PTMs 
The transcriptional activity of LXRs is highly dependent on the presence of coregulators which 
has been linked to several metabolic processes (Jakobsson et al., 2009; Kim et al., 2003; 
Huuskonen et al., 2004; Kim et al., 2008; Oberkofler et al., 2003). Coregulators constitutes large 
multisubunit protein complexes containing chromatin-remodelling and/or –modifying 
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enzymes with intrinsic histone acetylase (HAT)/ deacetylase (HDAC) and histone methylase 
(HMT)/demethylase (HDM) activities, depending on whether they act as activators or 
repressors, respectively (Kato et al., 2011). It has been assumed that that the unliganded LXRs 
are localized in the nucleus and interact with CRs, including nuclear receptor 
corepressor/silencing mediator of retinoic acid and thyroid receptor (NcoR/SMRT) (Wagner et 
al., 2003). However, recent chromatin immunoprecipitation (ChIP) studies, including ChIP-
sequencing (ChIP-Seq), have challenged this classical model. These studies put forward a more 
complex view, that ligands, pioneer factors, coregulators and posttranslational modifications 
(PTMs) play different roles in determining the LXR binding sites and actions in vivo (Boergesen 
et al., 2012; Heinz et al., 2010; Pehkonen et al., 2012). Furthermore, some coregulators have 
been shown to act as dual function activators/repressors, such as the coregulator protein 
receptor interacting protein 140 (RIP140). RIP140 has been shown to serve as a CA for LXR in 
lipogenesis but as a CR in gluconeogenesis independent of ligand activation (Herzog et al., 
2007). General mechanisms of coregulator actions are assumed to be conserved between LXRs, 
but based on the low amino acid sequence identity in the NTD (32%) and the hinge domain 
(25%) it is possible that they contain novel isotype specific interaction surfaces. Also, the 
specific coregulator requirement to lipogenic LXR target genes in response to different feeding 
regiments under normal and diabetic conditions remain largely unexplored. In addition to 
ligand binding, LXRs can be posttranslationally modified by phosphorylation, acetylation, and 
sumoylation, affecting their target gene specificity, stability, and transactivating and 
transrepressional activity, respectively (Li et al., 2007; Ghisletti et al., 2007; Chen et al., 2006; 
Yamamoto et al., 2007). We have recently shown that LXR can be modified by O-
GlcNAcylation in response to glucose (see section 4.3), increasing its transactivation of the 
SREBP1c promoter (Anthonisen et al., 2010). PTMs may alter the structural conformation of 
LXR thereby modifying the affinity of coregulators that determines whether a target gene is 
induced or suppressed. Modulation by PTMs can occur both in the absence and presence of 
natural ligand tuning LXR activities in a cell- and gene-specific manner (Rosenfeld et al., 2006) 
depending on the nutritional stimuli.  
3. LXR in hepatic de novo lipogenesis 
3.1. LXR lipogenic target genes 
In addition to being central regulators of cholesterol metabolism, the LXRs are involved in 
induction of fatty acid and triglyceride (TG) biosynthesis in response to feeding. De novo 
lipogenesis ensures that excess acetyl-CoA, which is an intermediate product of glucose 
metabolism, is converted into fats and subsequent TGs. LXRs are involved in hepatic 
lipogenesis through direct regulation of SREBP1c and ChREBP expression (Repa et al., 2000; 
Cha & Repa, 2007; Shimano, 2001). SREBP1c is a well described transcriptional regulator of 
hepatic lipogenesis (Shimano, 2001), and together with LXR and glucose-regulated ChREBP 
(see section 4.1), it controls expression of essential enzymes in lipogenesis, lipid storage and 
secretion (Fig. 3). SREBP1c deficiency does not fully abolish the expression of genes involved 
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Figure 3. Regulation of hepatic lipogenesis by LXR, SREBP1c and ChREBP. 
in hepatic lipogenesis. SREBP1c null mice treated with an LXR agonist results in induction 
of a subset of lipogenic genes and a modest increase in fatty acid synthesis (Liang et al., 
2002), which implies that LXR can act independently of SREBP1c. In particular, the SCD1 
gene is directly regulated by LXR in response to synthetic ligands, also in the absence of 
SREBP1c (Chu et al., 2006). SCD1 is central in desaturation of saturated fatty acyl-CoAs 
important for formation of cholesterol esters (CEs) and TGs. Thus, specific LXR-mediated 
regulation of SCD1 can be explained by the essential role of LXR in limiting toxic free 
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cholesterol in response to diets rich in cholesterol and saturated fat. The expression of LXR 
in liver is rapidly upregulated by insulin in vivo, increasing mRNA expression of SREBP1c, 
malic enzyme (ME), ACC and FAS. Furthermore, expression of these lipogenic genes was 
abolished in insulin-injected LXR/ double knock out mice (Tobin et al., 2002), indicating 
an essential role for LXR in insulin-mediated regulation of hepatic lipogenesis. The 
mechanisms by which insulin activate LXR-mediated gene expression is not clearly 
understood, but may involve production of endogenous ligand for LXRα/β (Chen et al., 
2004) and/or by signal transduction mechanisms downstream of the IR affecting CA 
recruitment to LXRs and/or PTMs of LXRs. This will be discussed in more detail below. Of 
note, PKA-induced phosphorylation of LXR has been shown to inhibit the expression of 
SREBP1c in liver from mice via reduced DNA binding and CA recruitment (Yamamoto et 
al., 2007). Since glucagon/cAMP/PKA signaling may, at least in part, explain down-
regulation of SREBP1c expression in response to fasting, it is likely that PKA-mediated 
phosphorylation of LXR contributes to the fasting signal on SREBP1c.  
3.2. Putative mechanisms regulating LXR-mediated de novo lipogenesis in 
response to insulin 
Insulin is the most important anabolic hormone in the body, regulating many processes 
important for cellular growth and energy storage such as glucose uptake and metabolism, 
glycogen and lipid synthesis, gene transcription and translation. A classic action of insulin is 
to mediate a metabolic switch from fatty acid oxidation to synthesis and suppress hepatic 
glycogenolysis and gluconeogenesis in response to carbohydrate excess, a process that is 
largely regulated at the transcriptional level. In this way, hepatic insulin signaling maintains 
whole body energy homeostasis. In the insulin-resistant state, only the ability of insulin to 
suppress hepatic gluconeogenesis is lost, while its ability to activate lipogenesis is retained 
(Shimomura et al., 2000; Matsumoto et al., 2006; Brown & Goldstein, 2008). This bifurcated 
insulin resistance can be explained by failure of insulin to inhibit the gluconeogenic 
transcription factor Forkhead box protein O1 (FoxO1), but maintaining signaling to 
lipogenic transcriptional regulators including LXR and SREBP1c. 
3.2.1. The insulin signaling cascade 
The insulin signaling cascade is initiated by the binding of insulin to the extracellular -
subunits of the dimerized IR followed by autophosphorylation on several intracellular 
tyrosine residues on the IR. Insulin receptor substrate (IRS) is an essential protein docking 
onto the phosphorylated IR which in turn is phosphorylated itself on multiple tyrosine 
residues. This creates docking sites for src homology 2 (SH2) domain containing proteins. 
The best studied SH2 protein that binds to tyrosine phosphorylated IRS proteins is the 
regulatory subunit of the phosphoinositide 3-kinase (PI3K). PI3K catalyzes the formation of 
the lipid second messenger phosphatidylinositol (3,4,5) trisphosphate (PIP3), which is 
necessary to recruit downstream kinases. PIP3 generates a binding site for proteins 
containing Pleckstrin homology (PH) domains, such as 3’-phosphoinositide-dependent 
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protein kinase (PDK1), the serine/threonine kinase Akt/protein kinase B and possibly also 
mammalian target of rapamycin complex 2 (mTORC2). PDK and mTORC2 are both 
necessary for full activation of Akt downstream of the insulin receptor via PDK1-mediated 
phosphorylation of Akt on threonine 308 and mTORC2-mediated phosphorylation on serine 
472 (Saltiel & Kahn, 2001; White, 2003; Jacinto et al., 2006). All these events occur transiently 
in specific cholesterol rich plasma membrane microdomains called caveolae, generating a 
specific signaling unit for proper downstream insulin signaling where Akt plays a central 
role.  
3.2.2. Regulation by mTOR 
One of the targets of Akt is mTORC1 (Zoncu et al., 2011). Recent evidence suggests that 
mTORC1 is involved in LXR-mediated lipogenic gene transcription including induction of 
SREBP1c, FAS and ACC in liver from mice subjected to a high fat diet (Hwahng et al., 2009). 
The authors show that the mechanism by which mTORC1 activates LXR is via p70 S6 kinase 
(S6K)-mediated phosphorylation of LXR. Conversely, in the fasted state, LXR was shown to 
be inhibited by AMPK-mediated phosphorylation. In agreement with these observations, Li 
et al (Li et al., 2010) showed that insulin-activated hepatic transcription of SREBP1c, FAS 
and SCD1 is mediated by mTORC1, however independent of S6K. As both LXR and 
SREBP1c induce lipogenic promoters in response to insulin, this might suggest that 
activation of LXR in response to insulin/nutrients is mediated, at least in part, by mTORC1 
and S6K, whereas insulin-signaling to SREBP1c requires mTORC2 independently of S6K, 
possibly via Akt-mediated inhibition of glycogen synthase kinase-3 (GSK3) (Hagiwara et al., 
2012). In this way, GSK3-mediated phosphorylation and degradation of SREBP1c is 
prevented by insulin signaling to mTORC2 and Akt. Of note, insulin has primarily been 
shown to act on the SREBP1c promoter by activating LXRs and not SREBP1c (Chen et al., 
2004) and the effect of insulin on SREBP1c is mainly at the posttranslational level. In a recent 
publication, mTORC1 was shown to phosphorylate a phosphatidic acid phosphatase, Lipin 
1, preventing its nuclear entry and subsequent inhibition of SREBP1c-mediated activation of 
the FAS promoter (Peterson et al., 2011). Furthermore, Yecies JL et al (Yecies et al., 2011) 
showed that Akt2 independently of mTORC1 downregulate the mRNA expression of 
insulin induced gene 2 (Insig2a), an inhibitor of SREBP1c. This finding has been debated by 
Wan M et al (Wan et al., 2011), who could not observe any downregulation of Insig2a by 
Akt2. They postulate that Akt2 acts independently of mTORC1 and SREBP1c, possibly via 
posttranslational mechanisms, and that nutrients have a direct role in the liver to promote 
lipogenesis by a process dependent on both mTORC1 and other insulin-dependent signaling 
pathways. In light of the above mentioned studies, both mTORC1 and mTORC2 (Soukas et 
al., 2009; Guertin et al., 2006; Lamming et al., 2012; Hagiwara et al., 2012) appear to play 
important roles in lipid synthesis and storage in hepatocytes. Further studies will reveal the 
relative roles of Akt1, Akt2, mTORC1/C2 and S6kinase on activation of LXR and SREBP1c in 
this regulation under insulin sensitive and insulin resistant conditions and cross-talk with 
glucose metabolism and signaling (Fig.4). 
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3.2.3. Regulation by FoxO1  
Another mechanism by which insulin may promote LXR-mediated SREBP1c transcription is 
through the transcription factor FoxO1. FoxO1, generally known as an activator of 
gluconeogenic genes during fasting, can repress the transactivating ability of LXR and 
cooperating transcription factors SREBP1c and Specificity protein 1 (Sp1) to activate 
SREBP1c transcription during fasting (Liu et al., 2010; Deng et al., 2012). FoxO1 does not 
seem to bind directly to the SREBP1c promoter, but appears to act as a repressor through 
protein-protein interactions, possibly by recruiting CR proteins (Deng et al., 2012). Upon 
feeding, FoxO1 is inhibited by insulin via PI3-kinase activation and phosphorylation by Akt, 
which excludes phosphorylated FoxO1 from the nucleus via association with the 14-3-3 
protein (reviewed in (Tzivion et al., 2011)). In this way, at least under insulin sensitive 
conditions, inhibition mediated by FoxO1 and associating CRs is relieved, enabling LXR, 
Sp1 and SREBP1c to activate the SREBP1c promoter in a cooperative fashion. Of note, an 
important role for the E-box transcription factor Upstream Stimulatory Factor (USF) in 
mediating insulin activation of the SREBP1c promoter has also been reported (Wong & Sul, 
2010). The relative roles of LXR, SREBP1c and cooperating transcription factors in regulation 
of the SREBP1c promoter after high-carbohydrate feeding under normal and insulin 
resistant conditions and the role of FoxO1 in this process in insulin resistance is currently 
not known. Recently, the role of Akt as a central regulator of both gluconeogenesis, through 
inhibition of FoxO1, and lipogenesis, through activation of mTORC1/2 in hepatic insulin 
signaling, was debated as the insulin resistant phenotype of mice lacking hepatic Akt1/2 
were normalized in mice with concomitant liver-specific deletion of FoxO1 (Lu et al., 2012). 
This work suggests that a major role for Akt as a metabolic regulator in response to insulin 
is largely to restrain FoxO1 activity, at least for suppression of liver glucose output. 
3.2.4. Regulation by insulin-mediated oxysterol production 
Considering the bifurcated nature of insulin resistance and the postulated central role of Akt 
in this process, a very recent work by Wu and Williams (Wu & Williams, 2012), put forward 
an interesting theory. They suggest that disturbance of a single molecule, NAD(P)H oxidase 
4 (NOX4), is sufficient to induce the key harmful features of insulin resistance. NOX4 is 
activated upon IR activation, generating a transient burst of superoxide (O2-) and its 
byproduct H2O2. This enhances signal transduction by disabling enzymes in the protein-
tyrosine phosphatase gene family. In this way, essential inhibiting enzymes in the insulin 
signaling cascade is blocked, notably the PI3K inhibitor PTEN and protein-tyrosine 
phosphatase-1B (PTP1B) (Wu & Williams, 2012). Intriguingly, NOX4 may also be the link 
between insulin signaling and production of oxysterol ligand for LXR, as NOX4 through its 
superoxide producing activity may mediate the production of oxygenated cholesterol. The 
evidence for this is that pharmacological inhibition of NOX4 blocked insulin-induction of 
SREBP1c mRNA in rat primary hepatocytes, even though phosphorylations upstream and 
downstream of mTORC1 remained responsive (Wu & Williams, 2012). Furthermore, NOX4 
is transiently localized to caveolae (Han et al., 2012), possibly via recruitment to the IR, 
placing the enzyme in close proximity to cholesterol-rich areas of the plasma membrane. A 
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complete summary of putative mechanisms of insulin-mediated signaling to LXR, SREBP1c 
and lipogenesis is depicted in Fig. 4. 
 
 
Figure 4. Insulin-mediated regulation of hepatic lipogenesis 
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4. Lipogenic gene expression in response to glucose metabolism  
Hepatic glucose metabolism activates the transcription of various genes encoding enzymes 
of glycolysis and lipogenesis independently of insulin. However, the initial modification of 
glucose into Glucose-6-phosphate (G6P) by the enzyme Glucokinase (GK; Hexokinase 4) 
required for transcriptional regulation by glucose is highly dependent on insulin (Bosco et 
al., 2000), possibly via SREBP1c (Foretz et al., 1999; Kim et al., 2004) in concert with LXR and 
Peroxisome Proliferator-Activated Receptor gamma (PPAR) (Kim et al., 2009). Thus the 
actions of glucose and insulin may be considered interdependent and that regulation of 
gene expression in response to glucose seems to require active LXR, SREBP1c and/or PPAR.  
4.1. Glucose regulation via ChREBP  
A majority of hepatic glucose-responsive genes is thought to be regulated by the 
transcription factor ChREBP (Yamashita et al., 2001; Ishii et al., 2004). ChREBP mediates 
transcriptional regulation of glycolytic and lipogenic enzymes and is particularly important 
for the induction of liver-pyruvate kinase (L-PK), one of the rate limiting enzymes of 
glycolysis, which is exclusively dependent on glucose (Matsuda et al., 1990; Dentin et al., 
2004). Furthermore, ChREBP is involved in regulating ACC and FAS in concert with LXR 
and SREBP1c in response to glucose and insulin, respectively, suggesting its involvement of 
the conversion of carbohydrates into fat (Joseph et al., 2002; Talukdar & Hillgartner, 2006). 
Moreover, stimulation by a synthetic LXR ligand, induces hepatic expression and activity of 
ChREBP (Cha & Repa, 2007). However, ChREBP is apparently not dependent on LXR for its 
hepatic expression and activity in mice fed a high carbohydrate/high fat diet (Denechaud et 
al., 2008), suggesting that ChREBP activity is reinforced by upstream LXR under certain 
nutritional conditions. At low glucose concentrations, the ChREBP protein is retained as an 
inactive phosphoprotein in the cytoplasm (reviewed in (Havula & Hietakangas, 2012)). The 
mechanisms by which glucose activate ChREBP is not clear, but involves induction of the 
ChREBP mRNA, dephosphorylation of the protein, shuttling to the nucleus and binding to 
the ChREBP response element at the promoter of its target genes (Uyeda & Repa, 2006). 
Early studies pointed to xylose 5-phosphate (Xu5P), an intermediate of the pentose 
phosphate pathway (PPP), as an activating signal through its ability to activate protein 
phosphatase 2A (PP2A) and subsequent dephosphorylation of ChREBP (Havula & 
Hietakangas, 2012). Recently, ChREBP was shown to be activated by fructose 2,6-
biphosphate (F2,6BP) in hepatocytes (Arden et al., 2012). The level of F2,6BP is regulated by 
the bifunctional enzyme 6-phosphofructokinase-2-kinase/fructose-2,6-biphosphatase 
(PFK2/FBP2). Thus, PFK2 catalyzes the synthesis and degradation of F2,6BP and as a result, 
the enzyme is involved in both glycolysis and gluconeogenesis. In the fed state, insulin and 
carbohydrates dephosphorylate PFK2 in the liver making the enzyme kinase dominant. 
Subsequently, F6P is converted to F2,6BP that activates PFK1, which in turn stimulates 
glycolysis (Fig. 6). Interestingly, LXR was recently shown to be a central regulator of hepatic 
PFK2 mRNA expression (Zhao et al., 2012). Activation of ChREBP in response to glucose 
appears to depend on multiple glucose metabolites, including G6P, X5P and F2,6BP. As LXR 
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is involved in regulation GK- and PFK2-expression in response to insulin, this may suggest 
that ChREBP is dependent on insulin signaling via LXR for proper substrate availability.  
4.2. Glucose metabolism via the hexosamine biosynthetic pathway and O-
GlcNAc signaling 
Glucose metabolism from F6P can follow the alternative hexosamine biosynthetic pathway 
(HBP) where the enzyme glutamine fructose-6-phosphate amidotransferase (GFAT) controls 
the first and rate limiting step (Fig. 5).  
 
Figure 5. Nutrient flux and O-GlcNAc modification of nucleocytoplasmatic proteins through the HBP 
The end product of this pathway is Uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc), an essential building block for N-and O-linked glycosylation of proteins and 
lipids. Cytoplasmic and nuclear proteins can be dynamically modified by O-linked -N-
acetylglucosamine (O-GlcNAc) on serine and threonine residues by the enzyme O-GlcNAc 
transferase (OGT) using UDP-GlcNAc as substrate. OGT is an essential enzyme as targeted 
deletion of this gene is lethal (Shafi et al., 2000). The enzyme O-GlcNAc transferase (OGA) 
hydrolyses the sugar analogous to protein dephosphorylation of phosphorylated proteins 
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by phosphatases (Hart et al., 2007; Love, 2005). Because O-GlcNAc levels on proteins appear 
to be sensitive to increasing flux through this pathway in response to nutrient excess, OGT 
can be considered as a general sensor of glucose availability that modifies proteins 
according to changes in UDP-GlcNAc levels. There is no identified consensus sequence for 
GlcNAcylation, and unlike the multiple genes encoding kinases, there is only a single X-
linked gene encoding the catalytic subunit of OGT in mammals (Shafi et al., 2000). For this 
reason, it has been hypothesized that OGT is the catalytic subunit in large transient enzyme 
complexes where interacting proteins are able to target OGT to its many substrates. Many 
transcription factors are modified by O-GlcNAc in the liver (Dentin et al., 2008; Housley et al., 
2008; Kuo et al., 2008; Ozcan et al., 2010). Interestingly, FoxO1 has been shown to be a target 
for O-GlcNAcylation in hepatocytes in response to hyperglycemia in the insulin resistant state, 
resulting in elevated transactivating capacity for FoxO1 against its gluconeogenic targets 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
reinforcing hepatic glucose production (Housley et al., 2008; Kuo et al., 2008). Moreover, this 
activation was later shown to be dependent on targeting of OGT to FoxO1 via interaction with 
the coactivator PGC1α, which itself was shown to be modified by O-GlcNAc upon interaction 
with OGT (Housley et al., 2009). As PGC1 have been shown to significantly amplify LXR-
mediated activation of the SREBP1c promoter (Oberkofler et al., 2003; Kim et al., 2008), a 
possible recruitment of an OGT/PGC1-complex to LXR on lipogenic target genes under 
insulin resistant conditions remains to be explored. Recently, ChREBP was also shown to be a 
target for O-GlcNAcylation in response to hyperglycemia (Guinez et al., 2011). Adenoviral 
overexpression of OGT in liver increased ChREBP O-GlcNAc modification, protein stability 
and transactivating activity of L-PK, as well as potentiating expression of ACC, FAS and SCD1 
mRNA expression in response to refeeding (Guinez et al., 2011). In contrast, hepatic 
overexpression of OGA reduced lipogenic protein content (ACC and FAS) and hepatic 
steatosis (excessive accumulation of TGs and CEs) in db/db mice, suggesting that enhanced 
OGT signaling to ChREBP and cooperating transcription factors/coregulators contributes to 
hepatic steatosis under insulin resistant conditions. 
4.3. O-GlcNAc signaling activates LXR and hepatic lipogenesis  
In 2007, glucose was reported as an endogenous ligand for LXR (Mitro et al., 2007). This has, 
however, been debated considering the hydrophobic nature of the ligand binding pocket 
(Lazar & Willson, 2007). Instead, we asked the question whether glucose exert its effect via 
hexosamine signaling and posttranslational O-GlcNAc modification of LXR. In a recent 
publication, we show that LXR is O-GlcNAc modified in response to high glucose (25 mM) 
in absence of insulin (cells cultured in 2 % serum, approximately 1-2 pmol/l insulin) and 
synthetic LXR-ligand in Huh7 cells, a human hepatoma cell line (Anthonisen et al., 2010). By 
pharmacological inhibition we demonstrated that hexosamine signaling and O-GlcNAc 
cycling mediates LXR dependent activation of the SREBP1c promoter in response to glucose. 
Furthermore, we observed increased O-GlcNAc modification of LXR in livers from refed 
mice and streptozotosin (STZ) treated diabetic mice corresponding with increased SREBP1c 
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mRNA expression. Moreover, general protein O-GlcNAcylation was increased in STZ-
treated hyperglycemic mice compared to control mice. Our results suggest that LXR is 
regulated by O-GlcNAc modification, thereby increasing its lipogenic potential. Whether O-
GlcNAc-LXR is able to transactivate other lipogenic genes in addition to SREBP1c, is currently 
under investigation in our laboratory. Our preliminary studies point to a role for O-GlcNAc-
LXR in upregulating ChREBP, FAS, ACC and SCD1 expression (Bindesbøll et al, 
unpublished). Furthermore, preliminary reChIP experiments in our laboratory (LXR ChIP 
followed by O-GlcNAc ChIP), show a strong induction of O-GlcNAc-associated LXR binding 
to LXRE on the promoters of SREBP1c, ChREBP, FAS and SCD1 in response to feeding both in 
control mice and STZ treated mice. Our study is supported by the observation that the 
SREBP1c promoter activity and protein levels of SREBP1c are increased in response to elevated 
glucose concentration in the mouse hepatocyte cell line H2-35 (Hasty et al., 2000). 
Furthermore, treatment with azaserine, an inhibitor of GFAT, completely suppressed 
expression of both cytoplasmic and nuclear SREBP1c protein, suggesting that hexosamine-
dependent O-GlcNAc signaling indeed is involved in glucose-induced SREBP1c mRNA 
expression, possibly via activation of LXR and/or cooperating transcription factors/CAs.  
In our in vitro studies, we observed only modest LXR/RXR transactivation of the SREBP1c 
promoter in high glucose/low insulin-treated cells. This might be explained by constitutive 
phosphorylation competing for the same site(s) as GlcNAc on LXR and/or inhibitory 
phosphorylation occurring on adjacent GlcNAc sites. Housley et al. (Housley et al., 2008) 
reported elevated O-GlcNAc on FoxO1 by high glucose and a subsequent reduction by insulin. 
They further showed that O-GlcNAc modification increased substantially on the insulin-
insensitive mutant FoxO1 lacking three AKT phosphorylation sites (T24A, S256A, S319A), 
resulting in increased FoxO1-dependent luciferase reporter activity. These observations imply 
overlapping and/or adjacent phosphorylation and GlcNAc sites on FoxO1. Indeed, the authors 
also identified several O-GlcNAc sites on FoxO1, one of which is adjacent to an Akt 
phosphorylation site (Thr317). In the case of LXR, which is activated by insulin, apparently in 
part via S6K-mediated phosphorylation (Hwahng et al., 2009), GlcNAcylation and 
phosphorylation might act synergistically on LXR in response to glucose and insulin. In fact, 
extensive cross-talk between O-GlcNAcylation and phosphorylation appear to contribute to 
the pathology of various diseases (Hart et al., 2011). In addition, GlcNAc and inhibiting 
phosphate (in response to fasting via PKA and/or AMPK) may compete for the same sites or 
are situated at different serines and/or threonines on LXR. Furthermore, GlcNAcylation and 
phosphorylation of LXR might be affected by ligand binding, which has been shown for 
SUMOylation and acetylation of LXR (Venteclef et al., 2010; Lee et al., 2009). A study by Torra 
et al. (Torra et al., 2008) reported that Ser198 phosphorylation of LXRα in RAW macrophages 
was induced by both synthetic and natural oxysterol LXR ligands and reduced by the RXR 
ligand 9-cis-retinoc acid. As such, we cannot exclude the possibility that LXR O-GlcNAcylation 
may be positively or negatively regulated by LXR and/or RXR ligands. From our in vitro 
GlcNAcylation results (Anthonisen et al., 2010) we believe that the major O-GlcNAc site(s) on 
LXRα and LXRβ resides in the N-terminal region containing the AF1 and DBD, indicating that 
O-GlcNAcylation occur independently of ligand. However, under hyperglycemic conditions, 
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ligand binding may recruit OGT to LXR via CAs, possibly PGC1 as reported for FoxO1 
(Housley et al., 2009). A more detailed mapping of the GlcNAc sites on LXR and site-directed 
mutagenesis as well as identification of coregulators of LXR under hyperglycemic conditions, 
are under way in our laboratory to elucidate the biological role of O-GlcNAc on LXR. A 
complete summary of putative mechanisms of glucose-signaling to LXR, ChREBP and 
lipogenesis is depicted in Figure 6. 
 
 
Figure 6. Glucose-mediated regulation of hepatic lipogenesis 
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5. Cross-talk between O-GlcNAc- and insulin signaling 
Studies in C.elegans demonstrate that O-GlcNAc cycling phenotypes are very sensitive to 
insulin as well as nutrient composition and that levels of insulin and nutrients influence 
the role of O-GlcNAc cycling and vice versa (Mondoux et al., 2011; Hanover et al., 2010; 
Hanover et al., 2010; Whelan et al., 2008). Intriguingly, O-GlcNAc-marked promoters in 
C.elegans are biased toward genes associated with PIP3 signaling, hexosamine 
biosynthesis, and lipid/carbohydrate metabolism (Love et al., 2010a). Defects in O-GlcNAc 
cycling results in deregulation of genes necessary for carbohydrate and lipid metabolism 
in response to insulin (Forsythe et al., 2006; Hanover et al., 2010) suggesting that both O-
GlcNAc cycling and insulin-signaling are required for a robust and adaptable response to 
hyperglycemia. Several studies have implicated O-GlcNAc cycling in the development of 
insulin resistance (reviewed in (Mondoux et al., 2011)). Mice overexpressing OGT in 
muscle or fat and mammalian cells overexpressing OGA develop insulin resistance 
(McClain, 2002; Arias et al., 2004; Vosseller et al., 2002). Later studies revealed that a 
subset of OGT was able to transiently translocate to the plasma membrane via association 
with PIP3 generated by insulin-activated PI3K (Yang et al., 2008). In response to increased 
glucose metabolism, PIP3-associated OGT can O-GlcNAcylate IR, IRS and Akt 
antagonizing insulin signaling (Yang et al., 2008; Whelan et al., 2010). Moreover, OGT 
may also interact with the mTOR pathway (Hanover et al., 2010). As mentioned in section 
3.2.3, the downstream target for insulin signaling, FoxO1, is also modified by O-GlcNAc, 
apparently via OGT recruitment to PGC1, providing another mechanism for OGT to 
contribute to insulin resistance, at least for sustained hepatic glucose production in 
response to hyperglycemia (Housley et al., 2009). Directing OGT to transcriptional targets 
implies that PGC1α can integrate multiple nutrient signals to regulate gene expression. 
Whether OGT via PGC1 or other CAs is also recruited to ChREBP- and LXR-regulated 
promoters is currently not known. OGT is recruited to and O-GlcNAcylate several 
coregulators and histone modifying enzymes (acetylases/deacetylases, 
metylases/demetylases) and even histones themselves (Fujiki et al., 2009; Hanover et al., 
2012; Fujiki et al., 2011; Sakabe et al., 2010). Depending on the nutritional stimuli, all 
components of the transciptional machinery from specific transcription factors to 
coregulators, histones and RNA polymerase II are subject to epigenetic regulation by 
acetylation, ubiquitinylation, SUMOylation, phosphorylation and/or O-GlcNAcylation 
(Rosenfeld et al., 2006; Venteclef et al., 2011; Love et al., 2010b; Kato et al., 2011). The fine-
tuning of these modifications determines whether a gene is activated or repressed. 
Furthermore, as the substrate specificity of OGT is believed to be spatio-temporally 
regulated by transient interactions with large enzyme complexes, its binding to PIP3 may 
not occur solely at the plasma membrane, as PI3K is also active in the nucleus where it is 
involved in regulation of protein-chromatin interactions, transcription and mRNA export 
(Viiri et al., 2012; Kebede et al., 2012; Okada & Ye, 2009). As protein O-GlcNAcylation is 
rapidly increased at both the plasma membrane and the nucleus in response to serum-
stimulation (Carrillo et al., 2011), OGT-binding to nuclear PIP3 may also be instrumental 
in transcriptional regulation in response to feeding. Interestingly, nonalcoholic fatty liver 
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disease is often accompanied by hepatic insulin resistance, metabolic syndrome, and 
diabetes (reviewed in (Scorletti et al., 2011)) and the sensitivity of OGT to glucose 
increases with decreasing insulin signaling (Mondoux et al., 2011). These findings suggest 
that elevated O-GlcNAc cycling on key nuclear proteins contributes to the development of 
hepatic steatosis. This notion is also in line with the above mentioned observation by 
Guinez et al (Guinez et al., 2011), where overexpression of OGA reduced hepatic steatosis 
in db/db mice. A complete summary of a putative glucose-insulin cross-talk in regulation 
of hepatic de novo lipogenesis is depicted in Fig. 7.  
 
 
Figure 7. Glucose-insulin cross-talk in regulation of hepatic lipogenesis 
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6. Concluding remarks 
In mice and humans, hepatic de novo lipogenesis is activated by a high intake of both glucose 
and fructose (Scorletti et al., 2011; Schwarz et al., 1995; Schwarz et al., 2003). Fructose 
increase hepatic hexosamine signaling (Hirahatake et al., 2011) and induce SREBP1c and 
ChREBP expression in hepatic cells (Matsuzaka et al., 2004; Haas et al., 2012; Koo et al., 
2009), which may, in part be mediated by LXR. The response of LXR to glucose has been 
debated (Lazar & Willson, 2007), but a recent study support the notion of LXR as a 
glucose/fructose sensor as high sucrose fed mice exhibit elevated hepatic expression of 
SREBP1c and increased TG levels, which was not observed in LXR/ double knock out 
mice (Korach-Andre et al., 2011). LXR increases lipogenesis, in part by activating SREBP1c 
and ChREBP proteins. Thus, in response to feeding, they can cooperately activate most of 
the genes required for hepatic lipogenesis and TG secretion. Whether hepatic LXR drives the 
expression of SREBP1c and/or ChREBP to the same degree under different nutritional 
conditions is currently not known, as most studies have been performed using synthetic 
LXR agonists. We have preliminary results showing that hepatic expression of SREBP1c and 
ChREBP is upregulated in refed control mice and to a lesser extent in STZ-treated 
hyperglycemic mice, which is not observed in LXR/ double knock out mice (Bindesbøll et 
al, unpublished). O-GlcNAc modification of LXR is increased in STZ-treated mice 
(Anthonisen et al., 2010) and we postulate that O-GlcNAc modification of LXR in response 
to glucose activates LXR and drives the expression of ChREBP and SREBP1c and in 
particular the lipogenic genes, ACC and SCD1. Furthermore, RNA Pol II ChIP-Seq data 
show reduced binding of RNA Pol II to the L-PK promoter and no binding of RNA Pol II to 
the SCD1 promoter in LXR / double knock out mice compared to control mice. Moreover, 
a novel LXRE immediately downstream of SCD1 was found, to which LXR bound more 
strongly than the previously published upstream LXR binding site (Boergesen et al., 2012). 
This suggests an important role for LXR as an upstream activator of ChREBP-mediated 
transcription and argues for LXR acting independently on the SCD1 promoter, at least 
under certain nutritional conditions. Previous studies have demonstrated that LXR directly 
activates key lipogenic genes (Joseph et al., 2002), most notably SCD1 in the liver of SREBP1c 
knockout mice (Liang et al., 2002; Chu et al., 2006). Why there would be a need for LXR to 
activate lipogenic genes directly, may be explained by the nutritional conditions and 
redundancy in the system. Oxysterols bind the endoplasmic reticulum resident Insig protein 
and could inhibit the proteolytic maturation of SREBP1c (Radhakrishnan et al., 2007). This 
would limit transcription by SREBP1c, and direct activation by LXR would be required to 
stimulate lipogenesis. In the absence of active SREBP1c, however, LXR may act in concert 
with ChREBP in regulating lipogenic expression. A recent study show that hepatic 
overexpression of ChREBP induces SCD1 expression and hepatic steatosis, but not insulin 
resistance (Benhamed et al., 2012). Whether overexpression of ChREBP affected LXR protein 
expression and transactivation of the SCD1 promoter was not investigated in this study. In 
later studies, it would be interesting to investigate the SCD1 expression and activity in livers 
or hepatocytes with targeted deletion of ChREBP. Benhamed et al (Benhamed et al., 2012) 
also showed that ChREBP expression was increased in liver biopsies from patients with 
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steatosis and decreased in liver of patients with severe insulin resistance, suggesting that 
ChREBP, alone or in combination with LXR, drives SCD1 expression and steatosis 
independent of insulin resistance. This is in line with recent human studies showing no 
relationship between hepatic TG accumulation and insulin resistance (Cohen et al., 2011; 
Hooper et al., 2011). Thus, hepatic steatosis can either be the result or cause of hepatic 
insulin resistance. The mechanisms of hepatic insulin resistance is still not clear (Farese, Jr. et 
al., 2012), but may involve specific lipids, nutrition-induced metabolites and PTMs 
including O-GlcNAc. Hepatic TG synthesis may be a protective mechanism to limit 
accumulation of toxic free fatty acids, liver damage and fibrosis (Choi & Diehl, 2008) where 
particularly SCD1 seem to play a protective role (Li et al., 2009).  
As LXR is shown also to act anti-inflammatory in liver (Wouters et al., 2008; Venteclef et al., 
2010), LXR activation may be an important compensative mechanism in response to excess 
nutrients to limit liver damage, inflammation and fibrosis. SUMOylation is an important 
ligand-activated transrepressional PTM of LXR on inflammatory genes (Venteclef et al., 
2011) and future studies in our laboratory aim to elucidate a putative cross-talk between 
OGT and E3 ligases (SUMO conjugating enzymes) in liver in response to excess nutrients, 
especially high sugar levels (glucose and fructose). The relative roles of LXR, SREBP1c and 
ChREBP in driving lipogenesis is clearly dependent on both insulin and glucose signaling 
and cross-talk between these pathways. Both phosphorylation and GlcNAcylation appear 
instrumental in hepatic lipogenesis and future focus in our laboratory will be to elucidate a 
possible cross-talk between these PTMs, endogenous LXR ligands and interacting CAs in 
response to various feeding conditions (high glucose, fructose and/or fatty acids, 
cholesterol) and the impact on downstream ChREBP, SREBP1c and lipogenic enzyme 
expression and activity. ChIP and reChIP analysis in combination with loss of function 
studies have become powerful tools to analyze activation of specific genes by specific 
transcription factors in response to extracellular stimuli. By these methods, we anticipate 
that the signaling mechanisms and relative roles of LXR, ChREBP, SREBP1c and cooperating 
transcription factors in driving hepatic de novo lipogenesis will be revealed in the not too 
distant future. 
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